Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vallon Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel drugs for central nervous system disorders, announced that David Baker, President and CEO, will present at the Q3 Virtual Investor Summit on August 18, 2021, at 12:30 PM ET. The event will include a live video webcast of the presentation, accessible on the investor relations section of the Vallon website. Additionally, management will engage in virtual one-on-one meetings with qualified investors registered for the conference.
Details
News Market Reaction – VLON
The recorded move for VLON in the trading session of this news was +2.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18th 12:30 PM ET
PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the Q3 Virtual Investor Summit on Wednesday, August 18, 2021 at 12:30 PM ET.
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A live video webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website (www.vallon-pharma.com) and will be archived for 90 days following the event.
About Vallon Pharmaceuticals, Inc.
Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.
For more information about the company, please visit www.vallon-pharma.com or connect with us on LinkedIn or Twitter.
References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.